The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials to ​fight the widening Ebola outbreak in Democratic Republic of Congo, a Health Department spokesperson said.
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials to ​fight the widening Ebola outbreak in Democratic Republic of Congo, a Health Department spokesperson said.